Shots::sttohthshots:

• iBio enters a second statement of work under its MJDA with AzarGen- signed in 2018. The MJDA intends initial contract development and manufacturing of AzarGen’s biosimilars at iBio’s Bryan- Texas facility
• iBio plans to transfer its FastPharming Manufacturing System to AzarGen in South Africa to produce medicines in the African continent. By leveraging iBio’s FastPharming System- AzarGen will be benefited with the speed- quality and safety of the platform- but also deploy iBio’s support to make newer biologics available at lower costs in Africa
• In Sept’2019- AzarGen collaborated with iBio to manufacture research quantities of rituximab for bioanalytical testing. Following the completion of initial work- iBio will characterize additional supplies to enable pre-clinical studies comparing plant-made rituximab to the original molecule made using genetically engineered mammalian cells

Click here ­to­ read full press release/ article | Ref: iBio | Image: iBio